The Industry's Preeminent Event on Novel Drug Targets ...
The Industry's Preeminent Event on Novel Drug Targets ...
The Industry's Preeminent Event on Novel Drug Targets ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Inaugural n September 25 - 26, 2013<br />
Antibodies DTB Against Membrane Protein <strong>Targets</strong><br />
Part Two: Membrane Protein Producti<strong>on</strong>, Structural Biology and Characterizati<strong>on</strong><br />
»»<br />
Suggested <str<strong>on</strong>g>Event</str<strong>on</strong>g> Package<br />
September 23: FGN Producti<strong>on</strong> and Presentati<strong>on</strong> of Integral Membrane<br />
Proteins for Antibody Discovery Short Course 7<br />
September 24-25: Antibodies Against Membrane Protein <strong>Targets</strong><br />
C<strong>on</strong>ference Part One<br />
September 25-26: Antibodies Against Membrane Protein <strong>Targets</strong><br />
C<strong>on</strong>ference Part Two<br />
CVT<br />
Wednesday, September 25<br />
11:50 am Registrati<strong>on</strong><br />
1:30 pm Chairpers<strong>on</strong>’s Opening Remarks<br />
1:40 PLENARY KEYNOTE PRESENTATIONS<br />
See Page 3 for Details<br />
3:10-3:50 Refreshment Break in the Exhibit Hall with Poster Viewing<br />
STRUCTURAL BIOLOGY AND CHARACTERIZATION<br />
OF ANTIBODY-MEMBRANE PROTEIN INTERACTIONS<br />
3:50 Chairpers<strong>on</strong>’s Remarks<br />
Hassan Issafras, Ph.D., Senior Scientist, Molecular Interacti<strong>on</strong>s & Biophysics,<br />
Preclinical Research, XOMA Corp.<br />
4:00 Synthetic Antibodies to Probe the Structural and<br />
C<strong>on</strong>formati<strong>on</strong>al Diversity of GPCRs and <str<strong>on</strong>g>The</str<strong>on</strong>g>ir Signaling Complexes<br />
Arun Shukla, Ph.D., Assistant Professor, Medicine, Duke University Medical Center<br />
4:30 Sp<strong>on</strong>sored Presentati<strong>on</strong>s (Opportunities Available)<br />
5:00 Antibody Inhibiti<strong>on</strong> of Bacterial Manganese Transport<br />
Christopher Koth, Ph.D., Senior Scientist, Structural Biology, Genentech<br />
5:30 On-Cell, Soluti<strong>on</strong> Binding Affinity Measurements for<br />
Membrane <strong>Targets</strong><br />
Palaniswami Rathanaswami, Ph.D., Senior Scientist, Amgen, Canada<br />
6:00 <str<strong>on</strong>g>The</str<strong>on</strong>g>rapeutic Targeting of Homeostatic Chemokine Receptors<br />
with Antibodies<br />
Eldar Kim, Ph.D., Chief Scientific Officer, MSM Protein Technologies, Inc.<br />
6:30 Close of Day<br />
Thursday, September 26<br />
7:30 am Registrati<strong>on</strong><br />
MEMBRANE PROTEIN EXPRESSION AND<br />
IMMUNIZATION TECHNOLOGIES<br />
8:00 Breakfast Interactive Breakout Discussi<strong>on</strong> Groups<br />
9:05 Chairpers<strong>on</strong>’s Opening Remarks<br />
Partha Chowdhury, Ph.D., Principal Scientist, MedImmune<br />
9:10 Evoluti<strong>on</strong> of Stable and High Expressing GPCRs for Structure<br />
Determinati<strong>on</strong> and as Screening <strong>Targets</strong><br />
Pascal Egloff, Ph.D., Scientist, Plückthun Laboratories, Biochemistry Institute,<br />
University of Zürich, Switzerland<br />
9:40 Applicati<strong>on</strong> of Tetrahymena <str<strong>on</strong>g>The</str<strong>on</strong>g>rmophila as an Alternative<br />
Platform for Difficult to Express Immunogens<br />
Gregory Carven, Ph.D., Associate Research Fellow, Head of Hybridoma<br />
Research, Pfizer<br />
10:10 Coffee Break in the Exhibit Hall with Poster Viewing<br />
10:55 Immunizati<strong>on</strong> Strategy for Multiplex Target Validati<strong>on</strong> and<br />
<str<strong>on</strong>g>The</str<strong>on</strong>g>rapeutic Antibody Generati<strong>on</strong><br />
Partha Chowdhury, Ph.D., Principal Scientist, MedImmune<br />
11:25 Casting a Wide Net: Strategies to Meet the Challenges of<br />
Multi-Transmembrane <strong>Targets</strong><br />
Meredith Hazen, Senior Research Associate, Genentech<br />
11:55 Expressi<strong>on</strong> and Purificati<strong>on</strong> of Ligand Gated I<strong>on</strong> Channels<br />
and Applicati<strong>on</strong>s in <strong>Drug</strong> Discovery<br />
Arjan Snijder, Ph.D., Associate Principal Scientist, Discovery Sciences,<br />
AstraZeneca, Sweden<br />
12:25 pm Chicken M<strong>on</strong>ocl<strong>on</strong>al Antibodies to Native Sp<strong>on</strong>sored by<br />
C<strong>on</strong>formati<strong>on</strong> GPCRs and I<strong>on</strong> Channels<br />
Crystal<br />
B ioscience<br />
Bill Harriman, Ph.D., MBA, Chief Science Officer, Crystal<br />
Bioscience<br />
12:55 Native & Full Length Membrane Protein Sp<strong>on</strong>sored by<br />
Isolati<strong>on</strong> for Antibody Development and <strong>Drug</strong><br />
Discovery<br />
Anass Jawhari, Ph.D., CSO, Membrane Protein Alliance<br />
TECHNOLOGIES TO ENABLE ANTIBODY MEMBRANE<br />
TARGET DISCOVERY<br />
2:25 Chairpers<strong>on</strong>’s Opening Remarks<br />
Susan Lacy, Ph.D., Associate Director, AbbVie Bioresearch Center<br />
2:30 User Perspective <strong>on</strong> Commercial Technologies for Antibody<br />
Generati<strong>on</strong> to Multi-Spanning Membrane Proteins<br />
Susan Lacy, Ph.D., Associate Director, AbbVie Bioresearch Center<br />
3:00 Biacore Assay Development for GPCR Antibody <strong>Targets</strong><br />
Rick Chu, Ph.D., Principal Investigator, Genzyme<br />
3:30 Ice Cream Refreshment Break in the Exhibit Hall with Poster<br />
Viewing<br />
4:00 Generating <str<strong>on</strong>g>The</str<strong>on</strong>g>rapeutic Antibodies against Complex<br />
Membrane <strong>Targets</strong>: Case Studies Using the XenoMouse Discovery<br />
Platform<br />
Chadwick T. King, Ph.D., Principal Scientist, Amgen, Canada<br />
4:30 Using Stabilized Receptors to Generate <str<strong>on</strong>g>The</str<strong>on</strong>g>rapeutic<br />
Antibodies to GPCR <strong>Targets</strong><br />
Cath Hutchings, Ph.D., Antibody Project Manager, Heptares <str<strong>on</strong>g>The</str<strong>on</strong>g>rapeutics Ltd.,<br />
United Kingdom<br />
5:00 Isolati<strong>on</strong> of High-C<strong>on</strong>tent Single-Domain Antibodies from a<br />
Synthetic Library<br />
Ario de Marco, Ph.D., Director, TAb-IP Platform, Institut Curie, France<br />
5:30 Ligand and Antibody Binding Studies <strong>on</strong> immobilized<br />
Cannabinoid Receptor Type II (CB 2<br />
)<br />
Silvia Locatelli-Hoops, Ph.D., Scientist, Nati<strong>on</strong>al Institute <strong>on</strong> Alcohol Abuse &<br />
Alcoholism, Laboratory of Membrane Biochemistry and Biophysics, Nati<strong>on</strong>al<br />
Institutes of Health<br />
6:00 Close of C<strong>on</strong>ference<br />
DiscoveryOnTarget.com 19